RxDoctor Payments Data

Joseph Ortiz, MD

Internal Medicine · Grand Haven, MINPI 1326073792

Payments from drug & device makers

$1,570in general payments, 2019–2025

Across 96 payments — averaging $16.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$541
  • Pfizer$298
  • AstraZeneca$277
  • GSK$199
  • AbbVie$66
  • Boehringer Ingelheim$38
  • plus $151 from 7 others

What the payments were for

  • Food & beverage$1,54298%
  • Education$282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,570 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$106,464
Medicare patients
726
Services billed
1,794

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban169$185,152
MounjaroTirzepatide130$146,179
OzempicSemaglutide83$109,714
TrulicityDulaglutide71$102,729
FarxigaDapagliflozin Propanediol50$58,370
XareltoRivaroxaban30$45,536
JanuviaSitagliptin Phosphate32$39,015
JardianceEmpagliflozin21$33,095
MyrbetriqMirabegron34$30,237
ProliaDenosumab18$29,675
Spiriva HandihalerTiotropium Bromide25$20,877
RybelsusSemaglutide12$20,574
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog29$19,651
Atorvastatin Calcium965$19,623
TradjentaLinagliptin11$14,605

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$28$248,908201 claims
PfizerEliquis$298$185,152169 claims
Novo NordiskOzempic, Rybelsus$541$130,28895 claims
AstraZenecaFarxiga, Breztri Aerosphere$277$65,74462 claims
Boehringer IngelheimJardiance, Tradjenta$38$47,70032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Grand Haven

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →